- Home
- TERN vs ZLAB Comparison
TERN vs ZLAB Comparison
Compare TERN & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TERN | ZLAB |
|---|---|---|
| Founded | 2017 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.2B |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | TERN | ZLAB |
|---|---|---|
| Price | $27.52 | $19.85 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 6 |
| Target Price | $25.59 | ★ $57.22 |
| AVG Volume (30 Days) | ★ 5.6M | 941.0K |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $441,629,000.00 |
| Revenue This Year | N/A | $40.71 |
| Revenue Next Year | N/A | $50.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 24.14 |
| 52 Week Low | $1.87 | $19.51 |
| 52 Week High | $29.51 | $44.34 |
Technical Indicators
Market Signals| Indicator | TERN | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 74.11 | 22.69 |
| Support Level | $25.31 | $19.69 |
| Resistance Level | $29.51 | $20.47 |
| Average True Range (ATR) | 1.95 | 0.55 |
| MACD | 0.08 | 0.17 |
| Stochastic Oscillator | 81.51 | 11.76 |
Price Performance
Historical ComparisonAbout TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.